Sangamo Therapeutics Inc (NAS:SGMO)
$ 2.3 0.16 (7.48%) Market Cap: 479.89 Mil Enterprise Value: 468.41 Mil PE Ratio: 0 PB Ratio: 12.23 GF Score: 47/100

Q1 2022 Sangamo Therapeutics Inc Earnings Call Transcript

May 05, 2022 / 08:30PM GMT
Release Date Price: $4.3 (-6.11%)
Operator

Thank you for standing by, and welcome to Sangamo First Quarter 2022 Teleconference Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference over to your speaker today, Ms. Louise Wilkie. Thank you. Please go ahead.

Louise Wilkie

Good afternoon, and thank you for joining us today. With me on the call this afternoon are Sandy Macrae, Chief Executive Officer; Mark McClung, Chief Operating Officer; Prathyusha Duraibabu, Chief Financial Officer; Jason Fontenot, Chief Scientific Officer; Rob Schott, Head of Development; and Bettina Cockroft, Chief Medical Officer.

Slides from our corporate presentation can be found at our website, sangamo.com, under the Investors and Media section of the Events and Presentation page. This call includes forward-looking statements regarding Sangamo's current expectations. These statements include, but are not limited to, statements related to the therapeutic and commercial potential of our product candidates, the anticipated

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot